SEDI Insider filing browser
Filter by Company
×
Filter by $CAD Amount
×
Filter by Filing Type
Filter by Insider
×
 
Date Issuer Insider Transaction Amount New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
Recent filings
Filed 2024-03-01 13:35
Tx date 2024-03-01
$SONA
Sona Nanotech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+110,000 vol
535,000
Older filings
Filed 2023-07-17 14:52
Tx date 2023-07-13
$QPT
Quest PharmaTech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
$24,000
+300,000 vol
$0.08 each
1,050,000
Filed 2023-07-11 11:14
Tx date 2023-07-10
$SONA
Sona Nanotech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+150,000 vol
425,000
Filed 2023-03-30 10:55
Tx date 2023-03-28
$SONA
Sona Nanotech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
$29,750
+175,000 vol
$0.17 each
275,000
Filed 2022-07-25 10:52
Tx date 2022-07-21
$QPT
Quest PharmaTech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
$27,000
+300,000 vol
$0.09 each
750,000
Filed 2021-12-27 12:50
Tx date 2021-12-24
$BIO
Biome Grow Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+500,000 vol
1,000,000
Filed 2021-11-15 15:09
Tx date 2021-11-12
$SONA
Sona Nanotech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
$44,000
+100,000 vol
$0.44 each
100,000
Filed 2021-11-15 15:03
Tx date 2020-11-02
$SONA
Sona Nanotech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2021-07-09 18:54
Tx date 2021-07-05
$QPT
Quest PharmaTech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
$15,000
+150,000 vol
$0.10 each
450,000
Filed 2021-07-09 18:32
Tx date 2021-07-05
$QPT
Quest PharmaTech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
$10,000
+100,000 vol
$0.10 each
Filed 2021-07-09 18:31
Tx date 2021-07-05
$QPT
Quest PharmaTech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
300,000
Filed 2020-12-17 15:04
Tx date 2020-12-15
$SONA
Sona Nanotech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Warrants
53 - Grant of warrants
$15,625
+12,500 vol
$1.25 each
12,500
Filed 2020-12-17 15:04
Tx date 2020-11-02
$SONA
Sona Nanotech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Warrants
00 - Opening Balance-Initial SEDI Report
Filed 2020-12-17 15:03
Tx date 2020-12-15
$SONA
Sona Nanotech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$25,000
+25,000 vol
$1.00 each
25,000
Filed 2020-12-17 15:03
Tx date 2020-11-02
$SONA
Sona Nanotech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2020-09-21 21:27
Tx date 2020-07-31
$BIO
Biome Grow Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+500,000 vol
500,000
Filed 2020-09-21 21:26
Tx date 2018-10-03
$BIO
Biome Grow Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2020-04-02 17:56
Tx date 2020-03-30
$ASP
Acerus Pharmaceuticals Corporation
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
$104,645
+2,315,172 vol
$0.0452 each
2,715,172
Filed 2019-11-04 10:38
Tx date 2019-11-01
$ASP
Acerus Pharmaceuticals Corporation
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$1,600
+20,000 vol
$0.08 each
61,000
Filed 2019-11-04 10:38
Tx date 2019-10-21
$ASP
Acerus Pharmaceuticals Corporation
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$85.00
+1,000 vol
$0.085 each
41,000
Filed 2019-03-07
Tx date 2019-03-06
$ASP
Acerus Pharmaceuticals Corporation
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
$26,000
+200,000 vol
$0.13 each
400,000
Filed 2019-02-28
Tx date 2018-11-28
$ONC
Oncolytics Biotech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Rights Restricted Share Units
57 - Exercise of rights

-5,263 vol
Filed 2019-02-28
Tx date 2018-11-28
$ONC
Oncolytics Biotech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Rights Restricted Share Units
57 - Exercise of rights

-5,263 vol
31,008
Filed 2019-01-31
Tx date 2019-01-29
$QPT
Quest PharmaTech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
$18,000
+100,000 vol
$0.18 each
300,000
Filed 2018-11-30
Tx date 2018-11-28
$ONC
Oncolytics Biotech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+2,267 vol
4,688
Filed 2018-11-30
Tx date 2018-05-22
$ONC
Oncolytics Biotech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Rights Restricted Share Units
37 - Stock split or consolidation

-239,178 vol
28,137
Filed 2018-11-30
Tx date 2018-05-22
$ONC
Oncolytics Biotech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Common Shares
37 - Stock split or consolidation

-20,579 vol
2,421
Filed 2018-11-30
Tx date 2018-11-27
$ONC
Oncolytics Biotech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Rights Restricted Share Units
56 - Grant of rights

+8,134 vol
36,271
Filed 2018-11-30
Tx date 2018-05-22
$ONC
Oncolytics Biotech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
37 - Stock split or consolidation

-136,449 vol
16,051
Filed 2018-11-30
Tx date 2018-11-28
$ONC
Oncolytics Biotech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Rights Restricted Share Units
57 - Exercise of rights

-5,263 vol
31,008
Filed 2018-09-07
Tx date 2018-09-07
$ASP
Acerus Pharmaceuticals Corporation
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$3,640
+14,000 vol
$0.26 each
40,000
Filed 2018-08-31
Tx date 2018-08-30
$ASP
Acerus Pharmaceuticals Corporation
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$5,600
+20,000 vol
$0.28 each
26,000
Filed 2018-08-31
Tx date 2018-08-29
$ASP
Acerus Pharmaceuticals Corporation
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$560.00
+2,000 vol
$0.28 each
6,000
Filed 2018-08-29
Tx date 2018-08-28
$ASP
Acerus Pharmaceuticals Corporation
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$1,120
+4,000 vol
$0.28 each
4,000
Filed 2018-08-29
Tx date 2017-12-06
$ASP
Acerus Pharmaceuticals Corporation
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2018-01-04
Tx date 2018-01-02
$QPT
Quest PharmaTech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+50,000 vol
200,000
Filed 2017-12-13
Tx date 2017-12-12
$ONC
Oncolytics Biotech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
52 - Expiration of options
$-38,850
-17,500 vol
$2.22 each
152,500
Filed 2017-12-11
Tx date 2017-12-06
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
$72,000
+200,000 vol
$0.36 each
200,000
Filed 2017-12-11
Tx date 2017-12-06
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation)
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2017-12-04
Tx date 2017-12-01
$ONC
Oncolytics Biotech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Rights Restricted Share Units
56 - Grant of rights

+37,729 vol
267,315
Filed 2017-07-24
Tx date 2017-07-19
$QPT
Quest PharmaTech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
$22,500
+150,000 vol
$0.15 each
150,000
Filed 2017-07-24
Tx date 2017-07-13
$QPT
Quest PharmaTech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2017-07-24
Tx date 2017-07-13
$QPT
Quest PharmaTech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2017-01-19
Tx date 2017-01-16
$ONC
Oncolytics Biotech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Rights Restricted Share Units
56 - Grant of rights

+100,000 vol
229,586
Filed 2017-01-19
Tx date 2017-01-18
$ONC
Oncolytics Biotech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Options
52 - Expiration of options
$-22,500
-10,000 vol
$2.25 each
170,000
Filed 2016-10-06
Tx date 2016-10-03
$ONC
Oncolytics Biotech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Rights Restricted Share Units
56 - Grant of rights

+79,586 vol
129,586
Filed 2015-12-14
Tx date 2015-12-09
$ONC
Oncolytics Biotech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Rights Restricted Share Units
56 - Grant of rights
$20,000
+50,000 vol
$0.40 each
50,000
Filed 2015-12-14
Tx date 2004-04-05
$ONC
Oncolytics Biotech Inc.
Lievonen, John Mark
4 - Director of Issuer
Direct Ownership
Rights Restricted Share Units
00 - Opening Balance-Initial SEDI Report